

ArcherDx, HeliTec strategic partnership, 6/17

June 2017—ArcherDx and precision medicine company HeliTec (Shenzhen, China) announced a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration.

“We are pleased to work with Archer to co-develop cutting-edge, NGS-based diagnostic assays in China, particularly on those cancer types predominant in Asian populations,” Dongbin Zhou, CEO of HeliTec, said in a statement. “AMP technology has been widely adopted for a number of cancer sequencing applications, and this collaboration will bring a complete pipeline of AMP-based assays to the Chinese clinical market.”

All Archer NGS assays, including FusionPlex RNA assays, VariantPlex DNA assays, the Reveal ctDNA 28 kit, and the Immunoverse T-cell receptor kit, are available from HeliTec.

[ArcherDx](#), 303-357-9001